LLY

989.05

+1.09%↑

JNJ

239.88

+0.47%↑

ABBV

231.18

-0.16%↓

NVS

160.13

-0.43%↓

AZN

194.4

-1.62%↓

LLY

989.05

+1.09%↑

JNJ

239.88

+0.47%↑

ABBV

231.18

-0.16%↓

NVS

160.13

-0.43%↓

AZN

194.4

-1.62%↓

LLY

989.05

+1.09%↑

JNJ

239.88

+0.47%↑

ABBV

231.18

-0.16%↓

NVS

160.13

-0.43%↓

AZN

194.4

-1.62%↓

LLY

989.05

+1.09%↑

JNJ

239.88

+0.47%↑

ABBV

231.18

-0.16%↓

NVS

160.13

-0.43%↓

AZN

194.4

-1.62%↓

LLY

989.05

+1.09%↑

JNJ

239.88

+0.47%↑

ABBV

231.18

-0.16%↓

NVS

160.13

-0.43%↓

AZN

194.4

-1.62%↓

Search

CRISPR Therapeutics AG

Deschisă

SectorSănătate

55.89 -2.65

Rezumat

Modificarea prețului

24h

Curent

Minim

54.67

Maxim

57.03

Indicatori cheie

By Trading Economics

Venit

-24M

-131M

Vânzări

-25K

864K

Marjă de profit

-15,117.245

Angajați

393

EBITDA

-48M

-149M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+22.47% upside

Dividende

By Dow Jones

Următoarele câștiguri

4 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

1.1B

5.8B

Deschiderea anterioară

58.54

Închiderea anterioară

55.89

Sentimentul știrilor

By Acuity

19%

81%

32 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

CRISPR Therapeutics AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 mar. 2026, 23:01 UTC

Câștiguri

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

5 mar. 2026, 21:54 UTC

Câștiguri

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

5 mar. 2026, 21:35 UTC

Principalele dinamici ale pieței

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

6 mar. 2026, 00:00 UTC

Evenimente importante

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

5 mar. 2026, 23:46 UTC

Market Talk

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

5 mar. 2026, 23:33 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

5 mar. 2026, 23:27 UTC

Market Talk

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

5 mar. 2026, 22:54 UTC

Market Talk
Câștiguri

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

5 mar. 2026, 22:50 UTC

Market Talk

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

5 mar. 2026, 22:48 UTC

Câștiguri

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

5 mar. 2026, 22:46 UTC

Câștiguri

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

5 mar. 2026, 22:44 UTC

Câștiguri

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5 mar. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 mar. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 mar. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

5 mar. 2026, 21:35 UTC

Câștiguri

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5 mar. 2026, 21:32 UTC

Câștiguri

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5 mar. 2026, 21:26 UTC

Câștiguri

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

5 mar. 2026, 21:24 UTC

Câștiguri

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

5 mar. 2026, 21:23 UTC

Câștiguri

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

5 mar. 2026, 21:22 UTC

Câștiguri

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5 mar. 2026, 21:21 UTC

Câștiguri

Costco February Digitally-Enabled Sales Rose 21.8% >COST

5 mar. 2026, 21:21 UTC

Câștiguri

Costco Total Co Comparable Sales for February Rose 7.9% >COST

5 mar. 2026, 21:20 UTC

Câștiguri

Costco February Net Sales Were $21.69 B >COST

5 mar. 2026, 21:20 UTC

Câștiguri

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5 mar. 2026, 21:20 UTC

Câștiguri

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5 mar. 2026, 21:19 UTC

Câștiguri

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

5 mar. 2026, 21:18 UTC

Câștiguri

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

5 mar. 2026, 21:18 UTC

Câștiguri

Costco 2Q Same-Store Sales Up 7.4% >COST

5 mar. 2026, 21:15 UTC

Câștiguri

Costco 2Q EPS $4.58 >COST

Comparație

Modificare preț

CRISPR Therapeutics AG Așteptări

Obiectiv de preț

By TipRanks

22.47% sus

Prognoză pe 12 luni

Medie 70.21 USD  22.47%

Maxim 105 USD

Minim 33 USD

În baza a 16 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCRISPR Therapeutics AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

16 ratings

11

Cumpărare

4

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

33.5 / 38.27Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

32 / 351 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat